<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02862067</url>
  </required_header>
  <id_info>
    <org_study_id>HM20007722</org_study_id>
    <secondary_id>16MCPRP31100003</secondary_id>
    <nct_id>NCT02862067</nct_id>
  </id_info>
  <brief_title>SGLT2 Inhibition in Diabetes and Heart Failure</brief_title>
  <official_title>SGLT2 Inhibition in Diabetic Patients With Heart Failure With Reduced Ejection Fraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Heart Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the effects of SGLT2 inhibition with empagliflozin on cardio-respiratory fitness
      in patients with systolic heart failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators hypothesize that Sodium-GLucose coTransporters (SGLT)-2 inhibition will
      improve cardio-respiratory fitness (CRF) in patients with systolic heart failure.

      Participants treated with SGLT2 inhibitor Empagliflozin as standard of care will undergo
      assessments described below.

      The investigators will measure CRF with a validated cardiopulmonary exercise test at baseline
      and after 4 weeks of treatment received as standard of care, to determine whether SGLT2
      inhibition improves cardio-respiratory fitness assessed by changes in peak oxygen consumption
      (VO2)(mL/kg/min) and minute ventilation (VE)/carbon dioxide production (VCO2) slope, powerful
      independent clinical predictors of mortality in HF.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Actual">January 16, 2018</completion_date>
  <primary_completion_date type="Actual">January 16, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>SGLT2 inhibition effects on cardiorespiratory fitness (CRF).</measure>
    <time_frame>4 weeks</time_frame>
    <description>To measure the effects of Empagliflozin on cardiorespiratory fitness in patients with type 2 diabetes and heart failure with reduced ejection fraction or systolic heart failure. The effects on CRF are determined by measuring changes in peak VO2 (mL/kg/min) and the VE/VCO2 slope.</description>
  </primary_outcome>
  <enrollment type="Actual">18</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Heart Failure, Systolic</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Assessment of cardiorespiratory fitness</intervention_name>
    <description>Assessment of cardiorespiratory fitness</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with type 2 Diabetes Mellitus and Heart Failure with reduced Ejection Fraction or
        Systolic Heart Failure.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed clinical diagnosis of stable HF (NYHA class II-III) on maximally tolerated
             HF medical regimen including angiotensin-inhibitors, beta-adrenergic blockers, and
             loop diuretics

          -  Reduced left ventricular systolic function (LVEF&lt;50%) documented in the prior 12
             months

          -  Poorly controlled T2DM (HbA1c levels between 6.5% and 10.0%)

          -  18 years old and older.

        Exclusion Criteria:

          -  Type I diabetes;

          -  Type II diabetes with episodes of severe hypoglycemia &lt;50 mg/dl by history, frequent
             changes in anti-diabetic regimen class in the past 3 months or with a prior episode of
             diabetic ketoacidosis (any time);

          -  Open label treatment with SGLT2 inhibitors (within the past month);

          -  Treatment with thiazolidinedione (within the past month), which may induce volume and
             sodium retention;

          -  Chronic Kidney Disease (GFR&lt;45 ml/kg*min);

          -  Uncontrolled thyroid dysfunction (TSH&lt;0.4&gt;4.5 mcIU/ml);

          -  Pregnancy or of child-bearing potential;

          -  Active or recent (within 2 weeks) genital/urinal infection;

          -  Concomitant conditions or treatment which would affect completion or interpretation of
             the study including physical inability to walk or run on a treadmill such as
             decompensated HF (edema, NYHA class IV), significant ischemic heart disease, angina,
             arterial hypotension (BP systolic &lt;90 mmHg), orthostatic arterial hypotension,
             arterial hypertension (resting BP systolic &gt;160 mmHg), atrial fibrillation with rapid
             ventricular response, severe valvular disease, severe chronic obstructive or
             restrictive pulmonary disease, moderate- severe anemia (Hgb&lt;10 g/dl);

          -  Abnormal BP or heart rate response, angina or ECG changes (ischemia or arrhy- thmias)
             occurring during baseline cardio-pulmonary exercise testing;

          -  Chronic use of oral corticosteroids;

          -  Inability to give informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Salvatore Carbone, PhD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://onlinelibrary.wiley.com/doi/abs/10.1111/dom.13309</url>
    <description>Related Info</description>
  </link>
  <results_reference>
    <citation>Carbone S, Canada JM, Billingsley HE, Kadariya D, Dixon DL, Trankle CR, Buckley LF, Markley R, Vo C, Medina de Chazal H, Christopher S, Buzzetti R, Van Tassell BW, Abbate A. Effects of empagliflozin on cardiorespiratory fitness and significant interaction of loop diuretics. Diabetes Obes Metab. 2018 Aug;20(8):2014-2018. doi: 10.1111/dom.13309. Epub 2018 Apr 23.</citation>
    <PMID>29603546</PMID>
  </results_reference>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>August 1, 2016</study_first_submitted>
  <study_first_submitted_qc>August 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2016</study_first_posted>
  <last_update_submitted>July 12, 2018</last_update_submitted>
  <last_update_submitted_qc>July 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SGLT2</keyword>
  <keyword>type 2 diabetes mellitus</keyword>
  <keyword>systolic heart failure</keyword>
  <keyword>heart failure with reduced ejection fraction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Failure, Systolic</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The investigators plan to present the data promptly upon analysis as an abstract to a national meeting and/or a manuscript.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

